Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

Saxenda Approved for Weight Management The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor ...

Saxenda Approved for Weight Management Novo Nordisk announced that the FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like ...

Novo Nordisk A/S (NVO) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in adolescents ...

Objectives: The objective was to compare the use of low-dose liraglutide (LD-L) (Victoza) to the other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients without a type 2 diabetes (T2D) ...

Saxenda was approved in December 2014 to treat obesity, giving physicians another option for patients who are overweight and battling diabetes. Experts say payers need to take obesity as seriously as ...

A study showing that once-weekly subcutaneous semaglutide 2.4 mg (Wegovy, Novo Nordisk) produces greater long-term weight loss than once-daily injected liraglutide 3.0 mg (Saxenda, Novo Nordisk) among ...

Daily injections of Saxenda with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks, compared with placebo, in patients with type 2 diabetes ...

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non ...

Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: ...